Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy
White M, Schulte J, Xue L, Berger Y, Schuitevoerder D, Vining C, Kindler H, Husain A, Turaga K, Eng O. Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy. British Journal Of Cancer 2020, 124: 564-566. PMID: 33100328, PMCID: PMC7851380, DOI: 10.1038/s41416-020-01130-x.Peer-Reviewed Original ResearchConceptsProgrammed death-ligand 1 expressionProgrammed death-ligand 1Malignant peritoneal mesotheliomaImmune checkpoint inhibitionCheckpoint inhibitionIntraperitoneal chemotherapyPeritoneal mesotheliomaLevel of PD-L1 expressionUpregulation of programmed death ligand 1Malignant peritoneal mesothelioma patientsTreatment-naive cohortPD-L1 expressionDeath-ligand 1Patient tumor biopsiesSomatic mutation burdenCytotoxic therapyTumor biopsiesMutational burdenGermline mutationsTreatment strategiesChemotherapyPatientsMultiple time pointsTime pointsMesothelioma
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply